Dupilumab is effective in both atopic dermatitis and severe eosinophilic asthma because it targets a shared pathogenic cytokine pathway. The specific mechanism is:
- A Direct neutralization of IgE, preventing mast cell degranulation and basophil activation
- B Anti-IL-5 receptor alpha blockade reducing eosinophil survival and differentiation
- C Blockade of the IL-4 receptor alpha subunit (IL-4Ralpha), preventing signaling by both IL-4 and IL-13, key type-2 (Th2) cytokines driving eosinophilic inflammation in both conditions ✓
- D Anti-TSLP (thymic stromal lymphopoietin) blockade at the epithelial-dendritic cell interface
Explanation
Dupilumab is a fully human monoclonal antibody targeting the IL-4 receptor alpha (IL-4Ralpha) subunit. This subunit is shared between the Type I IL-4 receptor (IL-4Ralpha/gamma-c, responds to IL-4) and the Type II receptor (IL-4Ralpha/IL-13Ralpha1, responds to both IL-4 and IL-13). By blocking IL-4Ralpha, dupilumab simultaneously inhibits signaling by both IL-4 and IL-13, which are the key Th2 cytokines driving type-2 inflammation in atopic dermatitis (barrier dysfunction, IgE class switching), asthma (mucus hypersecretion, airway hyperresponsiveness), chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis. Mepolizumab/benralizumab target IL-5 axis; omalizumab targets IgE; tezepelumab targets TSLP.
Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.